Novel Therapy for Acute Migraine Shows Promise in Phase 3 Clinical Trial

New England Journal of Medicine Paper Confirms That Treatment Eliminates Pain and Other Symptoms

July 10, 2019—(BRONX, NY)—A drug belonging to a new generation of acute migraine headache treatments was found to eliminate pain and reduce bothersome symptoms for people with migraine in a large-scale trial reported in the July 11 issue of The New England Journal of Medicine. The drug, rimegepant, is awaiting U.S. Food and Drug Administration approval and may offer advantages over currently available migraine medications. The study was led by researchers at Albert Einstein College of Medicine and Montefiore Health System.

“For the first time in nearly three decades, people with migraine not helped by existing medications may have a new option to find relief during attacks,” said Richard B. Lipton, M.D., the study’s first author and Edwin S. Lowe Professor and vice chair of the Saul R. Korey Department of Neurology at Einstein and director of the Montefiore Headache Center.

Richard B. Lipton, M.D.

Richard Lipton, M.D.

Debilitating Disorder

Migraine headache affects about 12 to 14% of people, or more than a billion individuals worldwide. This chronic neurologic disorder involves periodic attacks of head pain along with symptoms that may include nausea as well as sensitivity to light and sound. More than three-quarters of migraine sufferers experience at least one migraine attack per month, and more than half are severely impaired during their attacks.

Currently, many people with migraine take triptan drugs (examples include sumitriptan, eletriptan, and rizatriptan), which were introduced in the 1990s. Triptans halt acute migraines by stimulating serotonin receptors, which in turn reduces inflammation and constricts blood vessels. But triptans don’t help everyone, they can produce intolerable side effects, and—since they constrict vessels—shouldn’t be taken by people with cardiovascular disease (CVD) or major CVD risk factors.

New Mechanism for Relief

People not helped by triptans, or those who can’t take them, may benefit from the new class of drugs called gepants, which includes rimegepant. Gepants work by targeting the receptors for a small protein, called CGRP, long implicated in migraine. During migraine attacks, CGRP is released resulting in pain. Gepants relieve the pain and other symptoms of migraine by blocking the CGRP pathway.

The New England Journal of Medicine trial assessed rimegepant in a randomized double-blind trial involving more than 1,000 men and women with migraine at 49 centers in the U.S. The participants were instructed to take a tablet of rimegepant, or a matching placebo tablet, during a migraine attack, once moderate or severe pain developed. Before taking the tablet and for 48 hours afterwards, patients answered questions in an electronic diary concerning their pain and their most bothersome symptoms. Participants chose their most bothersome symptom from a list, including intolerance to light, intolerance to loud sounds, or nausea.  

For the first time in nearly three decades, people with migraine not helped by existing medications may have a new option to find relief during attacks.

Richard B. Lipon, M.D.

Two hours after taking their tablets, 19.6% of patients in the rimegepant group were free from pain compared with 12.0% in the placebo group—a statistically significant difference. Freedom from their most bothersome symptoms occurred in 37.6% of patients in the rimegepant group and 25.2% in the placebo group. Side effects were minimal, with nausea and urinary tract infections the only adverse effects reported in more than 1% of patients in each group and no adverse CVD effects observed.

“These results confirm that rimegepant’s mechanism of action—blocking the CGRP pathway—effectively relieves pain and associated symptoms that occur during acute migraine attacks,” said Dr. Lipton. “As someone who has studied CGRP blockers for more than a decade, I’m gratified to see their benefits confirmed in a large-scale clinical trial.”

The study is titled, “Rimegepant, an Oral Calcitonin Gene–Related Peptide Receptor Antagonist, for Migraine.” Other authors of the study are Robert Croop, M.D., Elyse G. Stock. M.D., David A. Stock, Ph.D., Beth A. Morris, B.A., Marianne Frost, M.A., Gene M. Dubowchik, Ph.D., Charles M. Conway, Ph.D., Vladimir Coric, M.D., and Peter J. Goadsby, M.D., Ph.D.

The clinical trial, led by Dr. Lipton, was sponsored by Biohaven, which makes rimegepant and may benefit financially from the results. Dr. Lipton is a paid consultant and a stockholder of Biohaven.

Novel Therapy for Acute Migraine Shows Promise in Phase 3 Clinical Trial

News Release

Novel Therapy for Acute Migraine Shows Promise in Phase 3 Clinical Trial

Wednesday, July 10, 2019

New England Journal of Medicine Paper Confirms That Treatment Eliminates Pain and Other Symptoms

News Release

Einstein Faculty Receive NIH Career Development Awards

Friday, October 28, 2016

Severe Headache in Pregnant Women: When to Worry

News Release

Severe Headache in Pregnant Women: When to Worry

Wednesday, August 19, 2015

New Findings by Montefiore and Einstein Researchers Offer First Clinical Recommendations

Migraine Attacks Increase Following Stress

News Release

Migraine Attacks Increase Following Stress

Wednesday, March 26, 2014

New Research Published in Neurology Explores Impact of Stress Reduction on Migraine Attacks

Newly Established Neuroscience Clinical Trials Center Could Bring Treatments to Patients Faster

News Release

Newly Established Neuroscience Clinical Trials Center Could Bring Treatments to Patients Faster

Thursday, December 01, 2011

Einstein and Montefiore, in Partnership with Hospital Affiliates, Establish NIH-Funded Center

Migraine May Double Risk of Heart Attack

News Release

Migraine May Double Risk of Heart Attack

Wednesday, February 10, 2010

Doctors Urged to Manage Cardiovascular Risk Factors of Migraine Sufferers

Overuse of Narcotics and Barbiturates May Make Migraine Worse

News Release

Overuse of Narcotics and Barbiturates May Make Migraine Worse

Tuesday, November 18, 2008

Einstein researchers find that an excess of commonly prescribed migraine medications can lead to increased headaches.

First Rigorous Test Of Magnetic Stimulation Device Shows Promise For Short-Circuiting Migraines

News Release

First Rigorous Test Of Magnetic Stimulation Device Shows Promise For Short-Circuiting Migraines

Friday, June 27, 2008

Migraine sufferers can take treatment into their own hands by zapping the painful headaches with a hand-held magnetic stimulation device, instead of gulping medication, suggests new data presented at the 50th Annual Scientific Meeting of the American Headache Society.